Advertisement

Topics

Lonza, Takeda Alliance Reaches Milestone

03:09 EST 11 Jan 2019 | Contract Pharma

Takeda’s ALUNBRIG granted marketing authorization for ALK+ non-small cell lung cancer

Original Article: Lonza, Takeda Alliance Reaches Milestone

NEXT ARTICLE

More From BioPortfolio on "Lonza, Takeda Alliance Reaches Milestone"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...